Tymlos

Chemical Nameabaloparatide
Dosage FormInjection (subcutaneous; 3120 mcg/1.56 mL)
Drug ClassAnalogs
SystemMusculoskeletal
CompanyRadius Health
Approval Year2017

Indication

  • For the treatment of postmenopausal women with osteoporosis at high risk for fracture
Last updated on 4/25/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tymlos (abaloparatide) Prescribing Information.2018Radius Health, Inc., Waltham, MA